secwatch.observer — SEC 8-K summary
======================================

Issuer:     AEON Biopharma, Inc. (AEON)
CIK:        0001837607
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001837607-24-000083
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AEON Biopharma plans biosimilar development of ABP-450 targeting BOTOX; FDA meeting set for Q3 2024
--------------------------------------------------------------------------------

- ABP-450 will be developed as a biosimilar using BOTOX as reference product under 351(k) pathway.
- Biosimilar initial advisory meeting with FDA scheduled for Q3 2024.
- Planned Phase 3 cervical dystonia study of ~400 patients to compare ABP-450 to BOTOX.
- No specific financial results for Q2 2024 were disclosed in the press release.
- Company notes development is subject to securing funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000083/0001837607-24-000083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1837607/000183760724000083/aeon-20240812x8k.htm
  HTML page:      https://secwatch.observer/filing/0001837607-24-000083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer